The primary objective is to compare the efficacy of lurasidone (20-120 mg/day) monotherapy with that of placebo in patients with Bipolar I Depression by assessing the change from baseline in the MADRS total score at Week 6.
The study evaluates the efficacy and safety of lurasidone compared with placebo in treating Bipolar I Depression.